Year Founded
2006
Ownership
Private
Employees
~1000
Therapeutic Areas
CardiovascularEndocrinologyOtherOncologyNeurologyInfectious Diseases
Stage
Commercial
Modalities
Small molecule

Arbor Pharmaceuticals General Information

Arbor Pharmaceuticals, now a subsidiary of Azurity Pharmaceuticals, markets FDA-approved prescription products in neuroscience, cardiovascular, and institutional markets. The company has a robust pipeline and focuses on underserved patient needs.

Contact Information

Website
Primary Industry
[ "Pharma" ]
Corporate Office
Atlanta, Georgia
United States

Drug Pipeline

centanafadine
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Arbor Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

NovaQuest Private Equity, JW Asset Management, KKR

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Arbor Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Arbor Pharmaceuticals's complete valuation and funding history, request access »

Arbor Pharmaceuticals Investors

KKR
Investor Type: Venture Capital
Holding: Minority
Signet Healthcare Partners
Investor Type: Venture Capital
Holding: Minority
JW Asset Management
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »